A Study in People With Abnormal Fat Levels in the Blood

Lilly

Status and phase: Completed; Phase 2

Conditions: Dyslipidemia

Treatments: Drug: placebo; Drug: PPAR alpha

Study type: Interventional

Funder types: Industry

Identifiers

NCT00116519

5750

H8D-MC-EMBB

Details and patient eligibility

About

The purposes of this study are to determine:

• The safety of the study medication and any side effects that might be associated with it;
• Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C) and high blood fats or triglycerides (TG);
• How much of the study medication should be given to patients;
• How the study medication compares to fenofibrate (Lofibra), a drug used for people with low levels of HDL-C and high levels of TG.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women between 18 and 80 years of age
• People with abnormal fat levels in the blood (low HDL, high TG)

Exclusion criteria

• People with diabetes
• People whose blood pressure is greater than 160/95 mm Hg, on or off blood pressure medicine
• People who have had frequent chest pain or unstable angina, a heart attack or a heart procedure, including stent placement, within the past 3 months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind